Recent advances in nanosized drug delivery systems for overcoming the barriers to anti-PD immunotherapy of cancer

Publication date: Available online 14 November 2019Source: Nano TodayAuthor(s): Xiaochen Liu, Dangge Wang, Pengcheng Zhang, Yaping LiAbstractCheckpoint blockade immunotherapy revolutionizes the field of cancer therapy, among which anti-programmed cell death (anti-PD) therapy is the most successful one in clinic. Despite the tremendous advancement, anti-PD therapy is still limited by barriers such as low response rate and immune related adverse effects (AEs), which are mainly resulted from poor intratumoral infiltration of cytotoxic T lymphocytes and off-tumor distribution of the anti-PD drugs. To address these issues, nanosized drug delivery systems (NDDS) have been fabricated to realize synergistic application with anti-PD drugs for anti-tumor immunity priming or enable targeting delivery of anti-PD drugs with versatile chemical properties. In this review, we summarize the major barriers for successful anti-PD therapy, highlight current advances in NDDS with improved anti-PD therapeutic benefits, and discussed the possible directions of the field.Graphical abstractCheckpoint blockade immunotherapy revolutionizes the field of cancer therapy in clinic. Various nanosized drug delivery systems (NDDS) have been fabricated to enhance the therapeutic benefits of anti-PD drugs or enable combined anti-PD therapies for more effective cancer immunotherapy. In this review, we summarize the major barriers for successful anti-PD therapy, highlight current advances in NDDS with improved an...
Source: Nano Today - Category: Nanotechnology Source Type: research